A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among ...

Results from a randomized, phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic ...

A randomized, phase 2 clinical trial shows that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from ...

Among four approaches, perioperative chemotherapy and trimodality therapy were associated with better survival outcomes in ...

Evie is receiving a chemotherapy treatment plan that is a result of decades of donor supported clinical trials. Donations ...

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse ...

In positive early data from the RCT, sacubitril/valsartan given over 24 weeks reduced signs of heart damage in cancer ...

The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...

"When you know that your granddaughter, who at that point wasn't even a year old, has already done that treatment, it made me ...

A widely used heart failure medication called sacubitril/valsartan was associated with a lower risk of heart damage compared ...

Selective Targeting and Reduction of CD19+ B Cells Observed with Each FT522 Dose in Study's First Low-dose Cohort without ...

Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...